Healthcare - Biotechnology - NASDAQ - US
$ 10.8
-5.26 %
$ 739 M
Market Cap
-3.39
P/E
INCOME STATEMENT
0
REVENUE
-235 M
OPERATING INCOME
-216 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Replimune Group, Inc.
| Revenue | 0 |
| Cost Of Revenue | 2.66 M |
| Gross Profit | -2.66 M |
| Operating Expenses | 235 M |
| Operating Income | -235 M |
| Other Expenses | -19 M |
| Net Income | -216 M |
Income Statement
Millions
| Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 | |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | ||||||||
| Cost Of Revenue | 2.7 | 2.4 | 4.6 | 4.1 | 1.8 | 0.1 | 0.1 | 0.1 |
| Gross Profit | (2.7) | (2.4) | (4.6) | (4.1) | (1.8) | (0.1) | (0.1) | (0.1) |
| OPERATING INCOME | ||||||||
| Operating Expenses | 234.8 | 174.2 | 115.1 | 77.1 | 53.1 | 28.4 | 17.0 | 8.2 |
| Selling, General and Administrative Expenses | 59.8 | 50.6 | 38.8 | 23.2 | 17.4 | 8.8 | 5.7 | 2.7 |
| Research and Development Expenses | 175.0 | 126.5 | 79.5 | 56.8 | 38.8 | 22.2 | 13.5 | 6.9 |
| Operating Income | (234.8) | (177.1) | (118.3) | (80.0) | (56.2) | (30.9) | (19.2) | (9.6) |
| PRE-TAX INCOME | ||||||||
| Interest Income Expense | (2.2) | 4.2 | 2.2 | 3.1 | 1.9 | 0 | 0 | 0 |
| Total Other Income | 19.4 | 3.1 | 0.3 | (0.9) | 3.6 | 0.1 | (0.5) | 1.9 |
| Pre-Tax Income | (215.4) | (174.0) | (118.0) | (80.9) | (52.6) | (30.8) | (19.7) | (7.7) |
| NET INCOME | ||||||||
| Tax Provision | 0.4 | 0.3 | 1.2 | 2.4 | 1.9 | 0.5 | (2.1) | 0.1 |
| Net Income | (215.8) | (174.3) | (118.0) | (80.9) | (52.6) | (30.8) | (19.7) | (7.7) |
| EPS | 3.24 | 2.99 | 2.26 | 1.75 | 1.54 | 1.33 | 0.64 | 0.36 |